{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:06:44Z","timestamp":1794002804719,"version":"4.8.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transfusion therapy is a key intervention in decreasing morbidity and mortality in patients with sickle cell disease (SCD). Current indications for acute and chronic transfusion therapy have significantly increased the number of RBC units transfused to patients with SCD worldwide. This review summarizes transfusion management for the treatment or prevention of neurologic and perioperative complications, acute chest syndrome, and acute anemia associated with SCD. Despite the recognized benefits of transfusion therapy, it is not without the risks of iron overload, alloimmunization, and delayed hemolytic transfusion reactions. Transfusional iron overload management includes automated RBC exchange, noninvasive imaging to monitor iron burden, and iron chelation with parenteral or oral agents. Although limited and extended RBC antigen matching reduces antibody formation, the prevalence of RBC alloimmunization in patients with SCD remains high. Recent studies demonstrate that RH genetic diversity in patients with SCD contributes to Rh alloimmunization, suggesting that even more refined RBC matching strategies are needed. Advances in molecular blood group typing offer new opportunities to improve RBC matching of donors and recipients and can be of particular benefit to patients with SCD.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.439","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":109,"title":["Transfusion therapy for sickle cell disease: a balancing act"],"prefix":"10.1182","volume":"2013","author":[{"given":"Stella T.","family":"Chou","sequence":"first","affiliation":[{"name":"Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111705380425700_B1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pbc.24179","article-title":"Indications and complications of transfusions in sickle cell disease","volume":"59","author":"Smith-Whitley","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019111705380425700_B2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpeds.2006.06.037","article-title":"Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia","volume":"149","author":"Hulbert","year":"2006","journal-title":"J Pediatr"},{"key":"2019111705380425700_B3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0002-9343(78)90772-6","article-title":"The natural history of stroke in sickle cell disease","volume":"65","author":"Powars","year":"1978","journal-title":"Am J Med"},{"issue":"3","key":"2019111705380425700_B4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1067\/mpd.2002.122498","article-title":"Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke","volume":"140","author":"Scothorn","year":"2002","journal-title":"J Pediatr"},{"issue":"3","key":"2019111705380425700_B5","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2010-01-261123","article-title":"Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease","volume":"117","author":"Hulbert","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2019111705380425700_B6","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111705380425700_B7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ajh.21901","article-title":"Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease","volume":"86","author":"Gyang","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111705380425700_B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bcmd.2011.06.002","article-title":"Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia","volume":"47","author":"Bishop","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"2019111705380425700_B9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00277-008-0670-x","article-title":"Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease?","volume":"88","author":"Brousse","year":"2009","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111705380425700_B10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111705380425700_B11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jpeds.2010.03.007","article-title":"Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease","volume":"157","author":"Enninful-Eghan","year":"2010","journal-title":"J Pediatr"},{"issue":"4","key":"2019111705380425700_B12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/pbc.21430","article-title":"Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia","volume":"50","author":"McCarville","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019111705380425700_B13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/pbc.24392","article-title":"National trends in incidence rates of hospitalization for stroke in children with sickle cell disease","volume":"60","author":"McCavit","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"2019111705380425700_B14","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111705380425700_B15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2010-12-326298","article-title":"Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II","volume":"118","author":"Abboud","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111705380425700_B16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood-2006-11-057893","article-title":"Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia","volume":"110","author":"Zimmerman","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111705380425700_B17","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood-2004-07-2704","article-title":"Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience","volume":"105","author":"Gulbis","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111705380425700_B18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08880010903360367","article-title":"Design of the silent cerebral infarct transfusion (SIT) trial","volume":"27","author":"Casella","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"2019111705380425700_B19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pbc.22282","article-title":"Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"54","author":"Pavlakis","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2019111705380425700_B20","first-page":"CD007843","article-title":"Blood transfusions for treating acute chest syndrome in people with sickle cell disease","volume":"1","author":"Alhashimi","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2019111705380425700_B21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-3476(95)70025-0","article-title":"Effect of transfusion in acute chest syndrome of sickle cell disease","volume":"127","author":"Emre","year":"1995","journal-title":"J Pediatr"},{"issue":"25","key":"2019111705380425700_B22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111705380425700_B23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1537-2995.2008.02075.x","article-title":"Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults","volume":"49","author":"Turner","year":"2009","journal-title":"Transfusion"},{"issue":"6","key":"2019111705380425700_B24","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pbc.22211","article-title":"Erythrocytapheresis in children with sickle cell disease and acute chest syndrome","volume":"53","author":"Velasquez","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111705380425700_B25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.2006.06409.x","article-title":"Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2","volume":"136","author":"Styles","year":"2007","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111705380425700_B26","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111705380425700_B27","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/blood-2010-11-261834","article-title":"How I treat acute chest syndrome in children with sickle cell disease","volume":"117","author":"Miller","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111705380425700_B28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mpd.2001.119593","article-title":"Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia","volume":"139","author":"Miller","year":"2001","journal-title":"J Pediatr"},{"issue":"3","key":"2019111705380425700_B29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.mph.0000157789.73706.53","article-title":"Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome","volume":"27","author":"Hankins","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2019111705380425700_B30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2141.2011.08999.x","article-title":"Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients","volume":"156","author":"Brousse","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111705380425700_B31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2003-01-0069","article-title":"Epidemiology of human parvovirus B19 in children with sickle cell disease","volume":"103","author":"Smith-Whitley","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111705380425700_B32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1056\/NEJM199507273330402","article-title":"A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group","volume":"333","author":"Vichinsky","year":"1995","journal-title":"N Engl J Med"},{"issue":"9870","key":"2019111705380425700_B33","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","article-title":"The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial","volume":"381","author":"Howard","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"2019111705380425700_B34","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111705380425700_B35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bpobgyn.2011.10.001","article-title":"The obstetric management of sickle cell disease","volume":"26","author":"Howard","year":"2012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"4","key":"2019111705380425700_B36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.12061","article-title":"Challenges of alloimmunization in patients with haemoglobinopathies","volume":"159","author":"Chou","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111705380425700_B37","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1537-2995.2010.03045.x","article-title":"Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center","volume":"51","author":"Lasalle-Williams","year":"2011","journal-title":"Transfusion"},{"issue":"9","key":"2019111705380425700_B38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/pbc.24530","article-title":"Alloimmunization in sickle cell anemia in the era of extended red cell typing","volume":"60","author":"O'Suoji","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019111705380425700_B39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2013-03-490623","article-title":"High prevalence of red blood alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors","volume":"122","author":"Chou","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111705380425700_B40","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1542\/peds.111.6.e661","article-title":"Delayed hemolytic transfusion reaction\/hyperhemolysis syndrome in children with sickle cell disease","volume":"111","author":"Talano","year":"2003","journal-title":"Pediatrics"},{"issue":"9","key":"2019111705380425700_B41","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1537-2995.2009.02199.x","article-title":"Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death","volume":"49","author":"Chadebech","year":"2009","journal-title":"Transfusion"},{"issue":"6","key":"2019111705380425700_B42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3324\/haematol.2010.038307","article-title":"Delayed hemolytic transfusion reaction in children with sickle cell disease","volume":"96","author":"de Montalembert","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111705380425700_B43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/ehm.09.2","article-title":"Hyperhemolysis syndrome in sickle cell disease","volume":"2","author":"Win","year":"2009","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2019111705380425700_B44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.transci.2010.12.014","article-title":"The role of molecular immunohematology in sickle cell disease","volume":"44","author":"Chou","year":"2011","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"2019111705380425700_B45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood.V95.1.12","article-title":"The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype","volume":"95","author":"Singleton","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111705380425700_B46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood.V93.1.385","article-title":"Molecular basis of weak D phenotypes","volume":"93","author":"Wagner","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2019111705380425700_B47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2002-01-0320","article-title":"The DAU allele cluster of the RHD gene","volume":"100","author":"Wagner","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111705380425700_B48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1537-2995.2009.02382.x","article-title":"Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization","volume":"50","author":"Tournamille","year":"2010","journal-title":"Transfusion"},{"issue":"1","key":"2019111705380425700_B49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000461956","article-title":"Rh haplotypes that make e but not hrB usually make VS","volume":"72","author":"Reid","year":"1997","journal-title":"Vox Sang"},{"issue":"3","key":"2019111705380425700_B50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.21307\/immunohematology-2019-372","article-title":"Molecular characterization of GYPB and RH in donors in the American Rare Donor Program","volume":"22","author":"Vege","year":"2006","journal-title":"Immunohematology"},{"issue":"6","key":"2019111705380425700_B51","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1537-2995.2010.02970.x","article-title":"Analysis of RhCE variants among 806 individuals in France: considerations for transfusion safety, with emphasis on patients with sickle cell disease","volume":"51","author":"Pham","year":"2011","journal-title":"Transfusion"},{"issue":"9","key":"2019111705380425700_B52","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1537-2995.2001.41091086.x","article-title":"Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial","volume":"41","author":"Vichinsky","year":"2001","journal-title":"Transfusion"},{"issue":"11","key":"2019111705380425700_B53","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1537-2995.2007.01434.x","article-title":"Blood bank management of sickle cell patients at comprehensive sickle cell centers","volume":"47","author":"Afenyi-Annan","year":"2007","journal-title":"Transfusion"},{"issue":"2","key":"2019111705380425700_B54","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5858\/2005-129-190-PMODRB","article-title":"Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories","volume":"129","author":"Osby","year":"2005","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2019111705380425700_B55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21307\/immunohematology-2019-140","article-title":"Antigen-matched red blood cell transfusions for patients with sickle cell disease at The Johns Hopkins Hospital","volume":"28","author":"Karafin","year":"2012","journal-title":"Immunohematology"},{"issue":"1","key":"2019111705380425700_B56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21307\/immunohematology-2019-141","article-title":"Directed blood donor program decreases donor exposure for children with sickle cell disease requiring chronic transfusion","volume":"28","author":"Roberts","year":"2012","journal-title":"Immunohematology"},{"issue":"1","key":"2019111705380425700_B57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1537-2995.2009.02435.x","article-title":"Red blood cell alloimmunization in sickle cell disease patients in Uganda","volume":"50","author":"Natukunda","year":"2010","journal-title":"Transfusion"},{"issue":"3","key":"2019111705380425700_B58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1423-0410.2009.01209.x","article-title":"Blood group genotyping: from patient to high-throughput donor screening","volume":"97","author":"Veldhuisen","year":"2009","journal-title":"Vox Sang"},{"issue":"2","key":"2019111705380425700_B59","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1423-0410.2009.01185.x","article-title":"DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen-matched blood in patients with sickle cell disease","volume":"97","author":"Ribeiro","year":"2009","journal-title":"Vox Sang"},{"issue":"2","key":"2019111705380425700_B60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1537-2995.2011.03288.x","article-title":"Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease","volume":"52","author":"Wilkinson","year":"2012","journal-title":"Transfusion"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/439\/1249586\/bep00113000439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/439\/1249586\/bep00113000439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T02:34:47Z","timestamp":1647657287000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/439\/20745\/Transfusion-therapy-for-sickle-cell-disease-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.439","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}